Correlation of inflammatory markers with depression and sleep disorders accompanying the prodromal stage of Parkinson’s disease DOI
Chengguang Zhang, Yu Zhang, Ke Xu

и другие.

World Journal of Psychiatry, Год журнала: 2025, Номер 15(3)

Опубликована: Фев. 26, 2025

Parkinson's disease (PD) is a common neurodegenerative disorder with increasing incidence and disability rates globally, placing heavy burden on patients their families. In the prodromal phase of PD, nonmotor symptoms, particularly depression sleep disorders, are frequent, profound effects progression patient quality life. Emerging research highlights critical role inflammatory markers-including interleukins tumor necrosis factor-in pathogenesis PD. These mediators participate in processes may induce or exacerbate depressive symptoms disorders by disrupting function hypothalamic-pituitary-adrenal axis affecting neurotransmitter, including serotonin, metabolism. Understanding correlations PD remains incomplete, limiting our ability to develop targeted interventions. This comprehensive review aims investigate specific between markers symptoms-particularly disorders-in The findings could have important practical applications, potentially leading development new diagnostic tools therapeutic strategies for managing By identifying understanding these correlations, healthcare providers better predict implement more effective treatments

Язык: Английский

Depression and Parkinson’s disease DOI

E. R. Bukhurova,

B. A. Alipkhanova,

D. Z. Shanibova

и другие.

Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery), Год журнала: 2024, Номер 8, С. 982 - 991

Опубликована: Авг. 17, 2024

Parkinson's disease is a progressive neurodegenerative with motor symptoms and non-motor impairments, including depression, observed in 2.7-90% of cases. Depression frequently underestimated diagnosed late due to its similarity disease, such as fatigue, sleep disturbances, hypomimia, etc. In approximately 25% patients, depression precedes symptoms, which may indicate connection the pathogenesis disease. The purpose study was analyze current data on pathophysiology, diagnosis, treatment patients results have demonstrated that pathophysiological mechanisms include neurodegeneration dopaminergic, noradrenergic, serotonergic neurons, neuroinflammation, impaired neuroplasticity. For timely treatment, especially those changes or should be regularly examined. Treatment based multimodal approach includes use supportive psychotherapy pharmacotherapy. Alternative methods exercise, cognitive behavioral therapy, transcranial magnetic stimulation, electroconvulsive therapy are also being explored. Thus, requires an individualized approach. Further research into this problem crucial develop improve patient management algorithms.

Язык: Английский

Процитировано

6

Intranasal AdipoRon Mitigated Anxiety and Depression-Like Behaviors in 6-OHDA-Induced Parkinson ’s Disease Rat Model: Going Beyond Motor Symptoms DOI

Negin Azizifar,

Gisou Mohaddes, ‬Rana Keyhanmanesh

и другие.

Neurochemical Research, Год журнала: 2024, Номер 49(11), С. 3030 - 3042

Опубликована: Авг. 3, 2024

Язык: Английский

Процитировано

5

New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract DOI Creative Commons
María Sancho‐Alonso, Unai Sarriés-Serrano, Lluís Miquel-Rio

и другие.

Spanish Journal of Psychiatry and Mental Health, Год журнала: 2024, Номер unknown

Опубликована: Июль 1, 2024

Neuropsychiatric and neurodegenerative disorders are frequently associated with gastrointestinal (GI) co-pathologies. Although the central enteric nervous systems (CNS ENS, respectively) have been studied separately, there is increasing interest in factors that may contribute to conditions affecting both systems. There compelling evidence serotonin (5-HT) play an important role several gut–brain disorders. It well known 5-HT essential for development functioning of CNS. However, most body's produced GI tract. A deeper understanding specific effects on provide basis new therapeutic targets. This review summarizes current data focusing ENS motility, particular emphasis novel aspects signaling where CNS comorbidities common, such as Parkinson's disease depressive

Язык: Английский

Процитировано

4

Correlation of inflammatory markers with depression and sleep disorders accompanying the prodromal stage of Parkinson’s disease DOI
Chengguang Zhang, Yu Zhang, Ke Xu

и другие.

World Journal of Psychiatry, Год журнала: 2025, Номер 15(3)

Опубликована: Фев. 26, 2025

Parkinson's disease (PD) is a common neurodegenerative disorder with increasing incidence and disability rates globally, placing heavy burden on patients their families. In the prodromal phase of PD, nonmotor symptoms, particularly depression sleep disorders, are frequent, profound effects progression patient quality life. Emerging research highlights critical role inflammatory markers-including interleukins tumor necrosis factor-in pathogenesis PD. These mediators participate in processes may induce or exacerbate depressive symptoms disorders by disrupting function hypothalamic-pituitary-adrenal axis affecting neurotransmitter, including serotonin, metabolism. Understanding correlations PD remains incomplete, limiting our ability to develop targeted interventions. This comprehensive review aims investigate specific between markers symptoms-particularly disorders-in The findings could have important practical applications, potentially leading development new diagnostic tools therapeutic strategies for managing By identifying understanding these correlations, healthcare providers better predict implement more effective treatments

Язык: Английский

Процитировано

0